0
0
MUMBAI — In the high-stakes world of personalized cancer treatment, the difference between a life-saving cure and a failed therapy often comes down to the health of a single type of cell. Researchers at the Indian Institute of Technology (IIT) Bombay have announced a significant breakthrough in how scientists recover these vital immune cells during the manufacturing process, potentially making advanced cancer treatments more effective and accessible.
The study, led by Professor Prakriti Tayalia and her team at the Department of Biosciences and Bioengineering, addresses a “hidden” bottleneck in the production of CAR T-cell therapy. By shifting from harsh chemical harvesting methods to a gentler enzymatic approach, the team has successfully recovered higher numbers of functional T-cells from lab-grown environments.
The Manufacturing Challenge: Beyond the “Living Drug”
CAR T-cell therapy is often described as a “living drug.” It involves extracting T-cells (the soldiers of the immune system) from a patient’s blood, genetically engineering them to recognize cancer, and multiplying them by the millions in a laboratory before re-infusing them into the patient.
However, growing these cells outside the human body is notoriously difficult. To thrive, T-cells require a 3D environment that mimics the body’s natural tissues. Researchers use scaffolds—microscopic, fiber-like structures—to provide this home.
“Cell recovery sounds simple on paper, but in practice, it turns out to be one of the biggest challenges,” explains Prof. Tayalia. “Without enough healthy cells, you cannot test them properly or use them for therapy.”
The Innovation: Mimicking Nature with Electrospinning
The IIT Bombay team utilized a technique called electrospinning to create scaffolds made of polycaprolactone (PCL). These scaffolds resemble a dense, microscopic fishing net. When Jurkat T-cells (a standard human cell line used for research) were introduced to these mats, they behaved exactly as they would in the human body: they migrated deep into the fibers and lodged themselves securely.
While this secure “lodging” is great for growth, it creates a secondary problem: how do you get the cells back out without killing them?
The “Gentle Touch” Breakthrough
Traditionally, scientists use an enzyme called trypsin to detach cells from laboratory surfaces. However, the IIT Bombay study, published in the journal Biomaterials Science, found that trypsin acted like a “chemical sledgehammer.”
-
The Problem with Trypsin: It often led to high rates of cell death and stripped away vital proteins on the cell surface. These proteins are the “antennae” the T-cell uses to communicate and identify cancer.
-
The Accutase Solution: The researchers turned to accutase, a milder enzyme. They found that cells recovered with accutase not only survived in significantly higher numbers but also retained their ability to form clusters—a critical prerequisite for cell division and immune activation.
“Harsh treatments to cells… can damage key surface proteins needed for immune signaling,” Tayalia noted. “Accutase appears mild enough to avoid this problem.”
Why This Matters for Public Health
The implications of this research extend far beyond the laboratory. Currently, CAR T-cell therapy is one of the most expensive medical treatments in the world, often costing hundreds of thousands of dollars per patient. A primary driver of this cost is the complex, inefficient manufacturing process.
If laboratories can recover a higher percentage of healthy, functional cells using the IIT Bombay method, it could:
-
Reduce Production Time: Getting more healthy cells faster means patients wait less time for their infusion.
-
Improve Efficacy: Higher-quality cells are more likely to successfully attack tumors once returned to the patient’s body.
-
Lower Costs: Increased efficiency in cell recovery could eventually lower the price point of these “miracle” therapies.
Expert Perspective and Context
While the results are promising, independent experts urge a balanced view.
“The move toward 3D electrospun scaffolds is a major step toward more ‘bio-realistic’ cell manufacturing,” says Dr. Aranya Chatterjee, an independent biotechnologist not involved in the study. “However, it is important to note that this study used Jurkat cells—a robust lab line. The real test will be replicating these results with primary T-cells harvested directly from oncology patients, which are often more fragile and exhausted by prior chemotherapy.”
Furthermore, the transition from PCL scaffolds to clinical-grade manufacturing requires rigorous regulatory approval to ensure no microscopic fibers remain in the final “product” re-entering the patient.
The Path Forward
The IIT Bombay study adds a crucial piece to the puzzle of domesticating advanced biotechnology. By focusing on the “boring” but essential mechanics of cell recovery, the researchers are paving the way for more reliable immunotherapy.
“If we want these advanced therapies to reach patients, every step matters,” says Prof. Tayalia. “How we grow cells, and how we retrieve them, can make a real difference.”
As India continues to emerge as a hub for affordable biopharmaceutical innovation, breakthroughs like these ensure that the next generation of cancer care is not just a scientific possibility, but a practical reality for those who need it most.
Key Statistics at a Glance
-
Target Cell Type: T-cells (specifically Jurkat T-cell line in this study).
-
Scaffold Material: Polycaprolactone (PCL).
-
Recovery Winner: Accutase (higher viability and protein retention compared to Trypsin).
-
Publication: Biomaterials Science (Royal Society of Chemistry).
References
- https://tennews.in/iit-bombay-develops-method-to-recover-t-cells-for-cancer-therapies/
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
